In our latest Psychedelic Patent Analysis, we take a deep dive into recent patent-related developments at two companies that are both pursuing 5-MeO-DMT for treatment-resistant depression (TRD): GH Research and Beckley Psytech. This case study raises questions not only about how these two specific companies’ IP might shake out, but also about how other types of exclusivity—such as data and market…


Previous articlePT488 – The Cost of War: Veterans’ Mental Health and Government Responsibility
Next articleIbogaine Advocates Seek Ohio Opioid Settlement Funds Following Failure in Kentucky